Argitalpenak (28) Jeronimo Martinez Garcia argitalpenak

2024

  1. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

    The Lancet, Vol. 403, Núm. 10421, pp. 31-43

  2. Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study

    Gynecologic Oncology, Vol. 185, pp. 202-211

2023

  1. Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 30, pp. 4768-4778

  2. Exercise during treatment for advanced cervical cancer

    BMJ Supportive and Palliative Care, Vol. 13, Núm. e3, pp. E960-E963

  3. HIPEC in Ovarian Cancer Is the Future… and Always Will Be? Results from a Spanish Multicentric Survey

    Cancers, Vol. 15, Núm. 13

  4. Incidence Trends and Main Features of Gastro-Intestinal Stromal Tumours in a Mediterranean Region: A Population-Based Study

    Cancers, Vol. 15, Núm. 11

  5. Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer

    Journal of Clinical Oncology

  6. Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A

    Signal Transduction and Targeted Therapy, Vol. 8, Núm. 1

  7. SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2707-2717

2022

  1. Interval cytoredutive surgery and HIPEC in advanced ovarian cancer with small-bowel disease: results and reflections

    Clinical and Translational Oncology, Vol. 24, Núm. 8, pp. 1542-1548

2021

  1. A growth modulation index-based geistra score as a new prognostic tool for trabectedin efficacy in patients with advanced soft tissue sarcomas: A Spanish group for sarcoma research (GEIS) retrospective study

    Cancers, Vol. 13, Núm. 4, pp. 1-15

  2. Acute renal disease in patients with ovarian peritoneal carcinomatosis treated with cytoreduction and HIPEC: the influence of surgery and the cytostatic agent used

    Langenbeck's Archives of Surgery, Vol. 406, Núm. 7, pp. 2449-2456

  3. CD8+ T lymphocytes are sensitive to NKG2A/HLA-E licensing interaction: role in the survival of cancer patients

    OncoImmunology, Vol. 10, Núm. 1

  4. Characteristics and prognosis of jejunoileal gastrointestinal stromal tumours (GISTs) in the era of imatinib: a comparative study with gastric GISTs

    Clinical and Translational Oncology, Vol. 23, Núm. 7, pp. 1368-1376

  5. Immunological Risk Stratification of Bladder Cancer Based on Peripheral Blood Natural Killer Cell Biomarkers

    European urology oncology, Vol. 4, Núm. 2, pp. 246-255

  6. SEOM clinical guideline in ovarian cancer (2020)

    Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 961-968

  7. Unresectable GIST liver metastases and liver transplantation: A review and theoretical basis for a new indication

    International Journal of Surgery, Vol. 94

  8. Urinary and fecal incontinence in patients with advanced ovarian cancer treated with CRS + HIPEC

    Surgical Oncology, Vol. 36, pp. 115-119

2020

  1. Identifying the incidence of respiratory complications following diaphragmatic cytoreduction and hyperthermic intraoperative intraperitoneal chemotherapy

    Clinical and Translational Oncology, Vol. 22, Núm. 6, pp. 852-859

  2. Kir+ cd8+ t lymphocytes in cancer immunosurveillance and patient survival: Gene expression profiling

    Cancers, Vol. 12, Núm. 10, pp. 1-20